BMS-863233 hydrochloride is a novel small molecule inhibitor that has shown promising results in preclinical studies for the treatment of various diseases. It is a potent and selective inhibitor of the protein kinase CK2, which plays a crucial role in cell proliferation, differentiation, and survival.
BMS-863233 hydrochloride can be synthesized using various methods, including chemical synthesis, enzymatic synthesis, and extraction from natural sources. The chemical synthesis involves the reaction of different chemical compounds to form the desired product. The enzymatic synthesis involves the use of enzymes to catalyze the reaction between the starting materials. The extraction from natural sources involves the isolation of the compound from plants or other natural sources. The efficiency and yield of each method vary depending on the starting materials, reaction conditions, and purification methods. Chemical synthesis is the most commonly used method for the synthesis of BMS-863233 hydrochloride, and it has been reported to have a yield of up to 50%. Enzymatic synthesis has also been reported to have a high yield, but it requires specific enzymes and reaction conditions. Extraction from natural sources is less efficient and yields lower amounts of the compound. Environmental and safety considerations are crucial in the synthesis or extraction of BMS-863233 hydrochloride. Chemical synthesis and enzymatic synthesis require the use of hazardous chemicals and solvents, which can have adverse effects on the environment and human health. Extraction from natural sources can also have environmental impacts if not done sustainably. Therefore, it is essential to consider the environmental and safety implications of each method and adopt sustainable practices.
Chemical Structure and Biological Activity
BMS-863233 hydrochloride has a chemical formula of C26H28N6O2S2.HCl and a molecular weight of 582.07 g/mol. The compound has a unique chemical structure that allows it to selectively inhibit CK2, a protein kinase that is overexpressed in various cancers and other diseases. The mechanism of action of BMS-863233 hydrochloride involves the inhibition of CK2, which leads to the disruption of cell proliferation, differentiation, and survival. The compound has shown potent activity against various cancer cell lines, including breast, lung, and prostate cancer. It has also shown activity against other diseases, such as inflammation, viral infections, and neurodegenerative disorders.
Biological Effects
BMS-863233 hydrochloride has various biological effects on cell function and signal transduction. It inhibits the phosphorylation of CK2 substrates, leading to the disruption of cell signaling pathways. The compound has also been shown to induce apoptosis, inhibit angiogenesis, and modulate the immune response. The potential therapeutic and toxic effects of BMS-863233 hydrochloride depend on the dose, duration of treatment, and the disease being treated. The compound has shown promising results in preclinical studies for the treatment of various cancers and other diseases. However, it can also have toxic effects on normal cells and tissues, leading to adverse side effects.
Applications
BMS-863233 hydrochloride has various applications in medical research, environmental research, and industrial research. In medical research, the compound has been studied for its role in drug development, clinical trials, and findings, benefits, and potential side effects. In environmental research, the compound has been studied for its effects on ecosystems, role in pollution management, sustainability, and environmental impact. In industrial research, the compound has been studied for its use in manufacturing processes, improving product quality and efficiency, and health and safety considerations.
Future Perspectives and Challenges
The current limitations in the use and study of BMS-863233 hydrochloride include the lack of clinical data, the potential for toxic effects, and the need for sustainable synthesis methods. Possible solutions and improvements include the development of more selective inhibitors, the use of alternative synthesis methods, and the adoption of sustainable practices. Future trends and prospects in the application of BMS-863233 hydrochloride in scientific research include the development of new therapies for various diseases, the identification of new targets for CK2 inhibition, and the integration of the compound into personalized medicine approaches. Conclusion: BMS-863233 hydrochloride is a promising small molecule inhibitor that has shown potent activity against various diseases. The compound has various applications in medical research, environmental research, and industrial research. However, the current limitations and challenges in the use and study of the compound need to be addressed to realize its full potential. The future trends and prospects in the application of BMS-863233 hydrochloride in scientific research are promising, and further studies are needed to fully understand its therapeutic potential.
Product FAQ
Q1: How Can I Obtain a Quote for a Product I'm Interested In?
To receive a quotation, send us an inquiry about the desired product.
The quote will cover pack size options, pricing, and availability details.
If applicable, estimated lead times for custom synthesis or sourcing will be provided.
Quotations are valid for 30 days, unless specified otherwise.
Q2: What Are the Payment Terms for Ordering Products?
New customers generally require full prepayment.
NET 30 payment terms can be arranged for customers with established credit.
Contact our customer service to set up a credit account for NET 30 terms.
We accept purchase orders (POs) from universities, research institutions, and government agencies.
Q3: Which Payment Methods Are Accepted?
Preferred methods include bank transfers (ACH/wire) and credit cards.
Request a proforma invoice for bank transfer details.
For credit card payments, ask sales representatives for a secure payment link.
Checks aren't accepted as prepayment, but they can be used for post-payment on NET 30 orders.
Q4: How Do I Place and Confirm an Order?
Orders are confirmed upon receiving official order requests.
Provide full prepayment or submit purchase orders for credit account customers.
Send purchase orders to sales@thebiotek.com.
A confirmation email with estimated shipping date follows processing.
Q5: What's the Shipping and Delivery Process Like?
Our standard shipping partner is FedEx (Standard Overnight, 2Day, FedEx International Priority), unless otherwise agreed.
You can use your FedEx account; specify this on the purchase order or inform customer service.
Customers are responsible for customs duties and taxes on international shipments.
Q6: How Can I Get Assistance During the Ordering Process?
Reach out to our customer service representatives at sales@thebiotek.com.
For ongoing order updates or questions, continue using the same email.
Remember, we're here to help! Feel free to contact us for any queries or further assistance.
Quick Inquiry
Note: Kindly utilize formal channels such as professional, corporate, academic emails, etc., for inquiries. The use of personal email for inquiries is not advised.
XL 413 hydrochloride(cas 1169562-71-3), also known as BMS-863233 hydrochloride, is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. XL413 demonstrated excellent plasma exposures in mice [100 mg/kg (PO): 141 lM (1 h), 81 lM (4 h)]. Prolonged treatment with XL413 (3 days) inhibited the cell proliferation (IC50 = 2685 nM), decreased cell viability (IC50 = 2142 nM) and elicited the caspase 3/7 activity (EC50 = 2288 nM) in Colo-205 cells.XL413 demonstrated an excellent exposure profile infull rat PK assay (dosed at 3 mg/kg: Cmax (PO) = 8.61 lM, AUC(po) = 75 lM h, CL = 117 mL/h kg, Vss = 0.55 L/kg, T1/2 = 2.32 h, F = 95%). Tumor bearing mice were administered XL413 orally at doses of 10, 30, or 100 mg/kg once daily (qd) for 14 days,XL413 was well tolerated at all the doses and regimens examined, with no significant body weight loss observed.
Enasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase 2 (IDH2) mutations, which are commonly found in acute myeloid leukemia (AML) patients. It was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of relapsed or refractory AML patients with IDH2 mutations. Enasidenib has shown promising results in clinical trials, and its potential applications in medical, environmental, and industrial research are being explored.
CO-1686 hydrobromide is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC50=21 nM).IC50 value: 21.5±1.7 nM (EGFRL858R/T790M), 303.3 ± 26.7 nM (EGFRWT)in vitro: CO-1686 is a potent inhibitor of EGFR L858R/T790M kinase (kinact/Ki = (2.41 ± 0.30) x 105 M-1s-1) and is approximately 22-fold selective over WT EGFR (kinactt/Ki = (1.12 ± 0.14) x 104 M-1s-1). CO-1686 potently inhibited proliferation in the mutant-EGFR NSCLC cellswith GI50 values ranging from 7 - 32 nM. In comparison, the GI50 value for A431 cells, an epidermoid cell line that is driven by amplified WT EGFR(19), was 547 nM. Two cell lines expressing WT EGFR in the presence of an N- or KRAS mutation (NCI-H1299 and NCI-H358,respectively) were inhibited by CO-1686 at a concentration of 4275 and 1806 nM, respectively.in vivo: CO-1686 displays high oral bioavailability (65%) and a relatively long half-life of 2.6 hours when dosed at 20 mg/kg. Tumor-bearing mice were dosed orally once daily with CO-1686 as single agent and its effect on tumor growth was determined in several EGFR dependent xenograft models. Continuous oral dosing of CO-1686 causes dose-dependent and significant tumor growth inhibition in all EGFR-mutant models examined. At 100 mg/kg/day CO-1686 causs tumor regressions in two Erlotinib-resistant models expressing the L858R/T790M EGFR mutation, the NCI-H1975 cell line xenograft and the patient-derived lung tumor xenograft (PDX) LUM1868, while Erlotinib had no inhibitory effect on tumor growth.
Quiflapon sodium is a synthetic compound that belongs to the class of selective 5-lipoxygenase inhibitors. It is a potent anti-inflammatory agent that has been extensively studied for its potential therapeutic applications in various diseases.
Favipiravir is an antiviral drug that has gained attention due to its potential use in the treatment of viral infections, including influenza and COVID-19. It was first developed in Japan in 2014 and has since been approved for use in several countries. This paper will provide an overview of Favipiravir, including its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, and future perspectives and challenges.
Naloxone is a medication used to reverse the effects of opioid overdose. It is an opioid antagonist that works by binding to the same receptors in the brain that opioids bind to, thereby reversing the effects of the opioids. Naloxone has been used for decades in emergency medicine and is now being used more widely in the community to prevent opioid overdose deaths. This paper will provide an overview of the synthesis and extraction methods of naloxone, its chemical structure and biological activity, its biological effects, applications in medical, environmental, and industrial research, and future perspectives and challenges.
Leucovorin, also known as folinic acid, is a synthetic form of folate, a B-vitamin essential for DNA synthesis and cell division. It is commonly used in combination with chemotherapy drugs to enhance their efficacy and reduce their toxicity. Leucovorin is also used in the treatment of certain types of anemia and in the prevention of birth defects.
Asparagusic acid is a sulfur-containing compound found in asparagus, which is responsible for the unique odor and taste of the vegetable. It has gained significant attention in recent years due to its potential therapeutic and environmental applications. This paper aims to provide a comprehensive review of asparagusic acid, including its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, and future perspectives and challenges.